Non-professional phagocytosis
Dead cells induced by heat were non-professionally phagocytized by living epithelial lung cells (BEAS2B) cells. Cell death was induced by overheating to 56°C for 45 min (Figure 1 A). The living cells adhered to the dead cells and phagocytized them within two to 10 hours (Figure 1 B). Phagocytotic rates ranged from less than 0.65% to 11.5%. Normal tissue cell lines (mean value 5.6%) phagocytized more than tumor cell lines (1.2%) (p=0.001) (Figure 1 C). In the process of phagocytosis, the overheated cell was completely engulfed by the living cell (Figure 1 D, E).
Senescence in tumor and normal-tissue cell lines
The aim was to study whether senescence is a trigger for non-professional phagocytosis observed for heat-induced cell death and whether senescent cells are being phagocytized by non-senescent cells. The chemotherapeutic agent camptothecin (CPT) was used to trigger senescence in BxPC-3 cells. After six days of incubation with 120nM or 200nM CPT cells were assessed for senescence induction by detection of high-mobility group AT-hook 2 (HMGA2) protein and Histone 3 tri-methylated at the 9th lysine residue (H3K9me3) heterochromatic foci formation, flow cytometric β-galactosidase staining as well as the estimation of the nuclear size in both axes. A clear change of the staining pattern (Figure 2A) and a distinct increase in nuclear size in both axes (Figure 2 B) was detected.
Additionally, the β-galactosidase activity was analyzed and a distinct increase up to day six by 120nM CPT was found (p<0.05) (Figure 2C, D). Thus, the 120nM CPT on day 6 induced a β-galactosidase+ activity in BxPC3+ cells of 42.7 (standard deviation ± 4.7%), in SBLF-7 of 52.7% ±4.2% and in SBLF-4 of 67.1 ±6.0%. Cells with a high percentage of senescent cells on day 7 also had increased levels of Annexin V and 7-Aminoactinomycin (7AAD) positivity (Figure 2 F). We selected the BxPC-3 cell line and the fibroblasts cell cultures SBL-F7 and SBLF-4 having 120nM CPT induced senescence rates of 78.0% (standard deviation ± 4.2%), 74.1%±7.2 and 97.8%±8.8, respectively (Supplementary figure 1).
Alternatively, the induction of senescence in BxPC-3 cells was studied using immunostaining (Figure 3A-D). After treatment with 120 nM campthothecin, the percentage of p21 staining as senescence marker increased from 19.9% to 80.1%. With 76.6% there were slightly less dead cells present compared to living cells (Figure 3B). In the BxPC-3 cell line, the CIC rates of non-senescent cells and senescent cells were determined. 1.3% of p21+ senescent cells and 2.1% of non-senescent cells had at least one dead cell phagocyted (Figure 3C).
Association of cell-in-cell structure formation and senescence in tumor and normal-tissue cell lines
Immunostaining was used to study non-professional phagocytosis of the three cell lines. Either cells were stained green or red by fluorescent live-cell stains (Figure 4 A-C). H3K9me3 antibodies were used to identify senescence cells. Only H3K9me3-positive cells were counted, which have had phagocytized CTOG-positive cells. No CIC events were observed, suggesting that cells showing signs of premature senescence are not phagocytized in vitro by viable cells. Conversely, it was not observed that living cells or senescent cells phagocytized living cells. H3K9me3+ senescent cells were co-incubated with CTOG+ necrotic cells and a similar high frequency of phagocytic event as for the viable cells (0.95%) was found (Figure 3 G-J). It indicates that senescent cells are capable of phagocytosis at comparable frequencies to non-senescent cells.
Cell-in-cell structures in clinical rectal cancer tissue samples
The frequency and prognostic relevance of cell-in-cell structures and senescent cells was studied in a rectal cancer cohort that was treated with neoadjuvant radiochemotherapy (RCT). A total of 96 patients with Tissue Micro Array (TMA) samples of tumor biopsy (“biopsy”), obtained during pretreatment endoscopy, were analyzed. In addition, TMA samples from the resected tumor at 6 weeks post-RCT were used for analysis. TMAs from these surgical specimens were available in 146 patients from the tumor core “central tumor”, in 97 patients in the tumor invasion zone (“invasive front”) and in 167 patients in surrounding normal tissue (“normal tissue”). The clinical and histological characteristics of the cohort are given in Table 1. Patients having pre-RCT biopsies, had a 5-year overall survival of 69.8%, a metastasis-free survival of 64.5% and a local recurrence-free survival of 70.1%, respectively (Figure 5A). Post-RCT patients had a 5-year overall survival of 67.8%, a metastasis-free survival of 57.8% and a local recurrence-free survival of 61.1%, respectively (Figure 5B). All TMAs were stained by antibodies, for anti-H3K9me3 (blue, nuclear) to detect senescent cells and for anti-E-Cadherin (red, membranous) to detect cell-in-cell structures (Figure 5C, D).
Prevalence of senescence and cell-in-cell structures in different tumor compartments
The median number of epithelial senescent cells/mm² was highest in the central tumor area (560 cells/mm2) followed by normal tissue (494 cells/mm2). In the biopsies and invasive front numbers of senescent cells were similar (360 cells/mm2 vs. 369 cells/mm2), respectively (Figure 5E). The mean numbers of epithelial cell-in-cell structures/mm² were most frequent in the invasive front (1.0 cell-in-cell/mm2) followed by the central tumor region (0.72 cell-in-cell/mm2) and biopsies (0.56 cell-in-cell/mm2). In normal tissue cell-in-cell phenomena were least common (0.08 cell-in-cell/mm2) (Figure 5F).
Prognostic significance of cell-in-cell and senescence rates in clinical rectal carcinoma tissue samples
The prognostic relevance of senescent cells and cell-in-cell structures for the following outcomes was analyzed: overall survival, metastasis-free survival, local recurrence-free survival and tumor-specific survival. For each outcome the cut-off values were determined by receiver operating characteristic (ROC) analysis resulting in specific cut off values for each individual analysis. Overall survival was clearly favorable for patients with a low number of senescent cells in pretreatment biopsies (5-year overall survival, 78.5% v. 61.2%, p=0.045) (Figure 6A) as well as central tumor areas (80% v. 76.8%, p=0.043) (Figure 6B).
Senescent cells in the invasive tumor front or normal tissue had no prognostic relevance, however (Figure 6 C, D). Cell-in-cell in biopsies were not significantly associated with prognosis. Patients having less than three cell-in-cell structures/mm² in the central tumor had a clearly improved overall survival (73.3% v. 46.9%, p=0.001) (Figure 6F). Patients having less than 0.2 cell-in-cell structure/mm² in their normal tissue (Figure 6H) also had a distinctly improved prognosis (71.8% v. 56.0%, p=0.042).
Moreover, low numbers of senescent cells in the biopsies (86.3% v. 74.4%, p=0.046) and low numbers of cell-in-cell structures (80.4% v. 65.7%, p=0.015) and senescent cells (89.0% v. 70.6%, p=0.014) in the central tumor area were associated with improved tumor-specific survival (Supplementary Figure 2). High numbers of senescent cells in the invasive tumor front were a predictor of a favorable local recurrence-free survival (73.3% v. 49.3%, p=0.024, Supplementary Figure 3). Patients with high senescent cell rates in biopsies (53.7% v. 75.6%, p=0.021) and central tumor (50.3% v. 73.7%, p=0.013) developed metastatic disease significantly more frequently than patients with low rates (Supplementary Figure 4).
Association of senescence with cell-in-cell structures in rectal cancer tissue samples
Each observed cell-in-cell structure (n=670) was photographed and was analyzed according to whether the engulfed and/or phagocytotic cell was senescent (Figure 7A-E).
Senescent cells were observed in 67% of all cell-in-cell structures. Most frequently senescent cells were engulfed by a non-senescent cell (39.4% of all cell-in-cell structures, Figure 7 B, F), followed by both participating cells not being senescent (33%, Figure 7C, F) and both cells being senescent (18.4%, Figure 7D, F). Non-senescent cells only rarely were engulfed by senescent host cells (9.3%, Figure 7E, F). This association was highly significant: Senescent cells were significantly more frequently internalized in cell-in-cell structures than constituting the external host cell (57.8% vs. 27.6%, p<0.001 Fisher’s exact test).
Combination of cell-in-cell and senescence rates as prognostic factors
In addition, the prognostic relevance of combined rates of senescence and cell-in-cell phenomena was studied. The combined group having high numbers of senescent cells and high cell-in-cell/mm² rates was associated with a poor overall survival (Figure 8A-D).
Therefore, high cell-in-cell and high senescent cell rates were compared to all others (Figure 8E-F). Patients with high senescent and cell-in-cell rates in the central tumor had a particularly unfavorable prognosis (73.3% v. 46.9%) (p<0.001, Figure 8F). Similarly, in the normal tissue patients with “high-high” rates showed an unfavorable prognosis (71.7% v. 46.7%) (p=0.011) (Figure 8H). Univariate and multivariate Cox’s regression analyses for overall survival were performed including clinical prognosticators and TNM stage. M stage (p<0.001) and combined high cell-in-cell/mm² with high senescence/mm² in the tumor post RCT (p=0.001) were independent prognostic factors for overall survival in multivariate analysis (Table 2).
Table 2: Univariate and multivariate analysis of overall survival according to Cox's proportional hazards model
|
Rectal cancer
|
Univariate analysis
|
Multivariate analysis
|
Variable
|
Hazard ratio
|
95% C.I.
|
p
|
Hazard ratio
|
95% C.I.
|
p
|
T stage (T4 [n = 21] v. T1/T2/T3 [n = 121 ])
|
0.596
|
0.272 - 1.306
|
0.196
|
0.555
|
0.254 - 1.213
|
0.140
|
N stage (N+ [n = 101] v. N0 [n = 41 ])
|
0.732
|
0.4 - 1.337
|
0.309
|
0.777
|
0.433 - 1.395
|
0.398
|
M stage (M+ [n = 23] v. M0 [n = 119 ])
|
5.233
|
2.682 - 10.208
|
<0.001
|
4.495
|
2.469 - 8.183
|
<0.001
|
Grading (3 + 4 [n = 27] v. 1 + 2 [n = 115 ])
|
1.329
|
0.674 - 2.619
|
0.411
|
---
|
---
|
---
|
Gender (female [n = 34] v. male [n = 108 ])
|
0.796
|
0.416 - 1.522
|
0.491
|
---
|
---
|
---
|
Age (> 58 years [n = 72] v. < 58 years
[n = 70 ])
|
1.772
|
1.002 - 3.132
|
0.049
|
1.635
|
0.942 - 2.839
|
0.081
|
Cell-in-cell > 3/mm2 [n = 31] v. ≤ 3/mm2
[n = 111 ]
|
1.237
|
0.617 - 2.477
|
0.549
|
---
|
---
|
---
|
Senescence > 328/mm2 [n = 89] v. ≤ 328/mm2 [n = 53 ]
|
0.895
|
0.116 - 6.928
|
0.915
|
---
|
---
|
---
|
Cell-in-cell > 3/mm2 and senescence > 328/mm2 [n = 26] v. others [n = 116 ]
|
2.849
|
0.332 - 24.434
|
0.340
|
2.623
|
1.46 - 4.713
|
0.001
|